Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease / 华中科技大学学报(医学)(英德文版)
Journal of Huazhong University of Science and Technology (Medical Sciences)
;
(6): 333-336, 2015.
Article
in English
| WPRIM
| ID: wpr-331064
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus (T2DM), dyslipidemia, central obesity and hypertension. Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors were widely used to treat T2DM. These agents improve glycemic control, promote weight loss and improve lipid metabolism. Recent studies have demonstrated that the GLP-1 receptor (GLP-1R) is present and functional in human and rat hepatocytes. In this review, we present data from animal researches and human clinical studies that showed GLP-1 analogues and DPP-4 inhibitors can decrease hepatic triglyceride (TG) content and improve hepatic steatosis, although some effects could be a result of improvements in metabolic parameters. Multiple hepatocyte signal transduction pathways and mRNA from key enzymes in fatty acid metabolism appear to be activated by GLP-1 and its analogues. Thus, the data support the need for more rigorous prospective clinical trials to further investigate the potential of incretin therapies to treat patients with NAFLD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Triglycerides
/
Clinical Trials as Topic
/
Therapeutic Uses
/
Drug Therapy
/
Glucagon-Like Peptide 1
/
Lipid Metabolism
/
Dipeptidyl-Peptidase IV Inhibitors
/
Non-alcoholic Fatty Liver Disease
/
Hypoglycemic Agents
Limits:
Animals
/
Humans
Language:
English
Journal:
Journal of Huazhong University of Science and Technology (Medical Sciences)
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS